VC  Pappas Ventures

http://www.pappasventures.com





     Office Locations:

2520 Meridian Parkway, Suite 400
Durham, NC 27713

Get all office locations for this firm with a National Database subscription.
 

Stages:

  • Early
  • Expansion
  • Growth
  • Seed


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Pappas Ventures is a life sciences venture capital firm located in the Research Triangle area of North Carolina. Since 1994 the firm has been investing in and nurturing promising young companies. Pappas has $350 million in capital under management and has invested in more than 50 portfolio companies throughout the United States. The firm invests exclusively in the life sciences sector: biotechnology, biopharmaceuticals, specialty pharmaceuticals, drug delivery, and medical devices. Pappas Ventures invests a substantial portion (about half) of its capital in early-stage companies that have yet to begin testing their products in clinical trials. Pappas invests the other half in companies whose lead products are at the Phase 1 or Phase 2 stage of development. Investment size ranges from $100,000 in a seed deal to as much as $6 million in a later-stage mezzanine transaction.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Arthur M. Pappas Managing Partner
    Ford S. Worthy JD Partner
    Matthew Boyer Controller
    Scott Weiner Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      08/02/2017


      Amplyx Pharmaceuticals


      CA


      $67,000,000


      Series C


     

    Portfolio companies include:


      Achillion Pharmaceuticals
        web link


      Afferent Pharmaceuticals
        web link


      Amplyx Pharmaceuticals
        web link


      Anthera Pharmaceuticals
        web link


      Athersys
        web link


      Balance Therapeutics
        web link


      BaroSense
        web link


      Bayhill Therapeutics
        web link


      BrainCells
        web link


      CardioDx
        web link


      CeNeRx BioPharma
        web link


      Chimerix
        web link


      Colucid Pharmaceuticals
        web link


      Evidation Health
        web link


      Gentis
        web link


      IlluminOss Medical
        web link


      IlluminOsss Medical
        web link


      LipoScience
        web link


      Liquidia Technologies
        web link


      Lumena Pharmaceuticals
        web link


      Marina Biotech
        web link


      MethylGene
        web link


      Milestone Pharmaceuticals
        web link


      Optherion
        web link


      Selventa
        web link


      Sensys Medical
        web link


      Syndax Pharmaceuticals
        web link


      TESARO
        web link


      Thrasos Therapeutics
        web link


      TyRx
        web link


      UltraGenyx Pharmaceutical
        web link


     

    Recent News: